Search
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigationalIpilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSA, YERVOY 5 mg/ml concentrate for solution for infusionSeliciclib
go.drugbank.com/drugs/DB06195InvestigationalR-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated
Categories: Heterocyclic Compounds, 2-RingSynonyms: 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, R-roscovitineTedisamil
go.drugbank.com/drugs/DB06200ExperimentalTedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administr...
Categories: Compounds used in a research, industrial, or household settingLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnLater Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008. … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphtholSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: SILOPROST® 8, FENANTA® 8 MGPrasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalSimilar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. … Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: PERKUNAL 5, PRASUGREL BETA 5 MG FTAFerumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigational[L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … [L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively
Categories: Compounds used in a research, industrial, or household settingLacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigationalLacosamide exhibits a stereoselective mode of interaction with sodium channels. … As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (R)-2-acetamido-N-benzyl-3- methoxypropionamide, (R)-LACOSAMIDE 1Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalpyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356 … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalHMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. … IPL 576,092 has previously been investigated as a treatment for asthma.